Suppliers and packagers for generic pharmaceutical drug: COBICISTAT

COBICISTAT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gilead Sciences Inc	TYBOST	cobicistat	TABLET;ORAL	203094	NDA	Gilead Sciences, Inc.	61958-1401-1	30 TABLET, FILM COATED in 1 BOTTLE (61958-1401-1)	2014-09-24

COBICISTAT SUPPLIER LANDSCAPE

Last updated: February 19, 2026

WHO ARE THE PRIMARY MANUFACTURERS OF COBICISTAT?

The supply chain for cobicistat, a pharmacokinetic enhancer used to boost the effectiveness of certain antiviral medications, is concentrated among a limited number of specialized manufacturers. These entities possess the complex chemical synthesis capabilities and regulatory compliance infrastructure required for pharmaceutical ingredient production.

Primary manufacturers include companies that have demonstrated the capacity to produce cobicistat under stringent Good Manufacturing Practices (GMP) guidelines. These manufacturers are typically integrated into the supply chains of major pharmaceutical companies developing or marketing cobicistat-containing drugs.

Key suppliers are assessed based on their production capacity, quality control systems, regulatory track record, and ability to meet the volume demands of global pharmaceutical markets. Patent landscape analysis reveals that the development and commercialization of cobicistat are closely tied to a few core manufacturing entities that have established production pathways and secured relevant intellectual property.

The global market for cobicistat is influenced by the patent exclusivity of the drugs it is formulated with. As patents for these drugs approach expiration, the demand for cobicistat may shift, impacting supplier strategies and market dynamics.

WHAT ARE THE KEY MANUFACTURING CAPABILITIES REQUIRED FOR COBICISTAT PRODUCTION?

The synthesis of cobicistat involves multi-step organic chemistry processes that require specialized facilities and expertise. Critical manufacturing capabilities include:

• Advanced Organic Synthesis: The ability to perform complex chemical transformations with high yields and purity. This includes proficiency in specific reaction types such as nucleophilic substitutions, carbonyl chemistry, and potentially chiral synthesis, depending on the stereochemical requirements of intermediates.
• Process Scale-Up: Expertise in transitioning laboratory-scale synthetic routes to large-scale commercial production. This involves optimizing reaction conditions, solvent use, and purification techniques to ensure cost-effectiveness and consistent quality at industrial volumes.
• Quality Control and Assurance: Robust analytical capabilities are essential to monitor reaction progress, identify impurities, and ensure the final Active Pharmaceutical Ingredient (API) meets stringent pharmacopeial standards (e.g., USP, EP) and customer specifications. This includes validated analytical methods for identity, purity, assay, and residual solvents.
• Regulatory Compliance: Facilities must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This encompasses rigorous documentation, process validation, equipment qualification, and quality management systems.
• Supply Chain Management: Secure sourcing of raw materials and intermediates is crucial. Manufacturers must have reliable suppliers for their own starting materials and a robust system for managing inventory and logistics.
• Containment and Safety: Handling potent chemical compounds requires specialized containment strategies and safety protocols to protect personnel and the environment.

The complexity of cobicistat synthesis contributes to a concentrated supplier base, as not all chemical manufacturers possess the necessary integrated capabilities and regulatory approvals.

WHICH COMPANIES ARE DIRECT OR INDIRECT SUPPLIERS OF COBICISTAT API?

Direct suppliers of cobicistat Active Pharmaceutical Ingredient (API) are typically specialized chemical manufacturers that produce the API for formulation into finished drug products. Indirect suppliers include companies that provide key intermediates or raw materials essential for cobicistat synthesis.

While specific commercial supply agreements are often confidential, publicly available information and patent filings can indicate key players in the cobicistat supply chain. Companies that have been involved in the development or manufacturing of cobicistat-related patents, or have a history of API production for other complex molecules, are likely candidates.

Based on typical pharmaceutical API manufacturing models, potential suppliers or manufacturers of intermediates for cobicistat include:

• Large Contract Development and Manufacturing Organizations (CDMOs): These organizations specialize in producing APIs for other pharmaceutical companies. They often have broad chemical synthesis capabilities and extensive regulatory experience.
• Specialized API Manufacturers: Companies with a dedicated focus on producing complex APIs for the pharmaceutical industry. These may include companies with established expertise in specific therapeutic areas or chemical classes.
• In-house Manufacturing by Innovator Companies: The original innovator pharmaceutical company may retain some or all of its cobicistat API manufacturing in-house, particularly during the patent-protected period of its related drug products.

Identifying specific commercial suppliers often requires access to proprietary supply chain data or direct engagement with pharmaceutical companies marketing cobicistat-containing products. However, regulatory filings and patent literature can provide insights into manufacturing pathways and potential producers.

WHAT IS THE PATENT LANDSCAPE SURROUNDING COBICISTAT MANUFACTURING?

The patent landscape for cobicistat is multifaceted, encompassing composition of matter patents, process patents for synthesis, and patents related to its use in specific drug formulations. These patents dictate the exclusivity periods and influence who can legally manufacture and sell cobicistat.

• Composition of Matter Patents: The primary patent covering the cobicistat molecule itself would have been among the earliest filed and would typically have the longest term of exclusivity.
• Process Patents: Numerous patents often cover specific methods of synthesizing cobicistat or key intermediates. These patents can provide secondary layers of protection, limiting competitors even after the main composition of matter patent expires. They may claim novel synthetic routes, specific reaction conditions, purification methods, or polymorphic forms.
• Formulation Patents: Patents covering the specific drug products that utilize cobicistat, such as fixed-dose combinations with antiviral agents. These patents influence the market demand for cobicistat.

Key Patent Considerations:

• Expiration Dates: The expiry of key patents, particularly the composition of matter patent and significant process patents, is a critical driver for generic competition and potential shifts in the supplier landscape.
• Freedom to Operate (FTO): Companies seeking to manufacture cobicistat, especially generic versions, must conduct thorough FTO analyses to ensure they are not infringing existing patents.
• Patent Litigation: Disputes over patent validity or infringement can significantly impact market access and supplier viability.
• Geographical Coverage: Patents are territorial. Manufacturing and sales strategies must consider patent protection in all relevant markets.

Example of Patent Activity:

Gilead Sciences, Inc. developed cobicistat and its initial applications. Patents filed by Gilead would have covered the initial discovery and manufacturing processes. As these patents approach expiration, other entities may seek to develop non-infringing processes to enter the market. The existence of multiple process patents can create a complex environment for generic manufacturers. For example, a patent might claim a specific chiral resolution step, while another claims a novel coupling reaction.

Analyzing patent filings with the United States Patent and Trademark Office (USPTO), European Patent Office (EPO), and other national patent offices provides detailed information on patented synthetic routes and their expiration timelines. These analyses are critical for R&D and investment decisions regarding cobicistat production.

HOW DO REGULATORY APPROVALS IMPACT COBICISTAT SUPPLIERS?

Regulatory approvals are a fundamental prerequisite for any company to supply cobicistat API for use in pharmaceutical products. These approvals ensure the quality, safety, and efficacy of the drug substance.

• Good Manufacturing Practices (GMP): Suppliers must demonstrate compliance with cGMP standards established by regulatory agencies worldwide, including the FDA, EMA, and others. This involves detailed facility inspections, process validation, and robust quality management systems.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory authorities. A DMF contains confidential, detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products. Pharmaceutical companies reference these DMFs in their New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs).
• Site Registrations and Inspections: Manufacturing sites must be registered with relevant health authorities. These sites are subject to periodic inspections by regulators to verify ongoing compliance with GMP.
• API Specifications and Testing: Each batch of cobicistat API must meet pre-defined specifications for identity, purity, strength, and quality. These specifications are reviewed and approved by regulatory bodies.
• Global Harmonization: While regional differences exist, there is increasing harmonization of regulatory requirements through initiatives like the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). However, suppliers must still meet specific requirements for each target market.

Impact on Suppliers:

• Barriers to Entry: The rigorous and costly nature of regulatory compliance creates significant barriers to entry for new API manufacturers. Established suppliers with existing GMP certifications and successful DMF filings have a competitive advantage.
• Supplier Qualification: Pharmaceutical companies rigorously audit and qualify their API suppliers to ensure they meet all regulatory and quality requirements. This process can be lengthy and demanding.
• Supply Chain Reliability: Regulatory non-compliance can lead to product recalls, import alerts, or facility shutdowns, disrupting the supply chain and impacting drug availability. Suppliers with a strong regulatory history are preferred.
• Generic Market Entry: For generic drug manufacturers to gain approval, they must demonstrate that their API is equivalent to the originator's API and is sourced from a compliant supplier. This often involves reviewing the DMFs of potential cobicistat API suppliers.

The regulatory landscape directly shapes the competitive dynamics by limiting the number of qualified suppliers and emphasizing long-term quality and compliance over short-term cost advantages.

WHAT ARE THE ECONOMIC DRIVERS AND MARKET DYNAMICS FOR COBICISTAT SUPPLY?

The economic drivers and market dynamics for cobicistat supply are primarily dictated by the demand for the finished pharmaceutical products in which it is incorporated, alongside patent exclusivity and pricing pressures.

Key Economic Drivers:

• Demand for Antiviral Therapies: Cobicistat is used to enhance the efficacy of certain HIV integrase inhibitors (e.g., elvitegravir) and Hepatitis C virus (HCV) protease inhibitors. The prevalence of these diseases and the adoption rates of the associated combination therapies are the primary drivers of cobicistat demand.
• Patent Exclusivity of Branded Products: During the patent-protected period of branded drugs containing cobicistat, demand is driven by the innovator company’s market penetration strategies, pricing, and formulary access.
• Generic Competition: Upon patent expiry of branded cobicistat-containing drugs, the entry of generic versions significantly increases the demand for cobicistat API from multiple manufacturers. This typically leads to price reductions for both the finished drug and the API.
• Pricing of Finished Drug Products: The wholesale acquisition cost of drugs incorporating cobicistat influences the acceptable price range for the API. High-priced branded drugs can support higher API costs, whereas generic competition drives down API prices.
• Manufacturing Costs: The cost of raw materials, energy, labor, regulatory compliance, and R&D for process optimization directly impacts the profitability of cobicistat manufacturing.

Market Dynamics:

• Concentrated Supplier Base: As previously noted, the specialized nature of cobicistat synthesis and stringent regulatory requirements result in a limited number of qualified API manufacturers. This can lead to a supplier-controlled market during periods of high demand and limited supply.
• Supply Chain Security and Resilience: Pharmaceutical companies prioritize supply chain security. They often seek to qualify multiple suppliers to mitigate risks associated with single-source dependency, geopolitical instability, or manufacturing disruptions.
• Geographic Shifts in Manufacturing: While some high-value API manufacturing remains in established markets like the US and Europe, there is a trend towards cost-effective production in regions like India and China, provided these suppliers meet stringent quality and regulatory standards.
• Long-Term Supply Agreements: Pharmaceutical companies often enter into long-term contracts with their preferred API suppliers, providing volume guarantees and price stability in exchange for assured supply and quality.
• Impact of New Entrants: The potential for new generic manufacturers to enter the market post-patent expiry can increase competition and drive down API prices. However, the ability to secure regulatory approvals and demonstrate non-infringing processes is crucial for these entrants.

The interplay of these economic factors and market forces shapes the competitive landscape for cobicistat suppliers, influencing production volumes, pricing strategies, and investment decisions in manufacturing capacity and technology.

WHAT ARE THE KEY CHALLENGES AND OPPORTUNITIES FOR COBICISTAT SUPPLIERS?

Cobicistat suppliers face a dynamic environment characterized by specific challenges and emerging opportunities. Navigating these requires strategic planning and operational excellence.

Key Challenges:

• Patent Expirations and Genericization: The primary challenge is the eventual expiration of patents for the branded drugs that utilize cobicistat. This leads to increased competition from generic manufacturers, driving down API prices and eroding profit margins for existing suppliers.
• Regulatory Scrutiny and Compliance Costs: Maintaining cGMP compliance is a perpetual and significant operational cost. Regulatory bodies continually update standards, requiring ongoing investment in facility upgrades, process validation, and quality systems. Non-compliance can result in severe penalties, including import bans and product recalls.
• Complex Synthesis and Quality Control: The multi-step synthesis of cobicistat requires sophisticated chemical expertise and advanced analytical capabilities to ensure consistent purity and to control impurities. Any deviation can lead to batch rejection and regulatory issues.
• Supply Chain Volatility: Sourcing specialized raw materials and intermediates can be subject to global supply chain disruptions, price fluctuations, and quality inconsistencies from upstream suppliers.
• Price Erosion: As competition intensifies with generic market entry, there is continuous pressure to lower API prices, impacting the profitability of manufacturing.
• Limited Therapeutic Applications: Cobicistat's utility is largely confined to specific antiviral regimens. Diversification into other therapeutic areas is not directly applicable to cobicistat itself, limiting market expansion opportunities for the API.

Key Opportunities:

• Emerging Market Demand: As global access to HIV and Hepatitis C treatments expands, particularly in developing economies, the demand for affordable cobicistat API from generic manufacturers is likely to increase.
• Process Innovation and Optimization: Suppliers that can develop and implement more efficient, cost-effective, and environmentally friendly synthetic routes for cobicistat can gain a competitive advantage. This includes reducing waste, improving yields, and minimizing energy consumption.
• Strategic Partnerships and Long-Term Contracts: Securing long-term supply agreements with major pharmaceutical companies or generic manufacturers provides revenue stability and volume predictability. Collaborating on process improvements can further solidify these relationships.
• Dual Sourcing and Supply Chain Resilience: Pharmaceutical companies increasingly seek to qualify multiple API suppliers to ensure supply chain resilience. Suppliers that can demonstrate robust quality systems and consistent delivery can capitalize on this trend by becoming secondary or tertiary suppliers.
• Expertise in Complex Generics: Companies with a proven track record in manufacturing complex APIs and navigating stringent regulatory pathways are well-positioned to capture market share in the post-patent era.
• Geographic Market Expansion: Targeting specific geographic regions with growing demand for antiviral therapies and where regulatory pathways are navigable can present significant growth opportunities.

Successfully managing these challenges while capitalizing on opportunities will determine the long-term viability and profitability of cobicistat suppliers.

Key Takeaways

• Cobicistat API manufacturing is concentrated among specialized chemical synthesis firms with extensive regulatory compliance capabilities.
• Key manufacturing requirements include advanced organic synthesis, process scale-up, rigorous quality control, and adherence to global cGMP standards.
• The patent landscape, encompassing composition of matter and process patents, dictates market exclusivity and influences the entry of generic manufacturers.
• Regulatory approvals, including GMP compliance and DMF filings, are critical barriers to entry and essential for supplier qualification.
• Economic drivers are primarily linked to the demand for HIV and Hepatitis C therapies, branded drug patent expirations, and subsequent generic competition, leading to pricing pressures.
• Suppliers face challenges from patent cliffs, regulatory burdens, and price erosion, but opportunities exist in emerging markets, process innovation, and securing long-term supply agreements.

Frequently Asked Questions

1. What is the primary function of cobicistat in pharmaceutical formulations? Cobicistat acts as a pharmacokinetic enhancer, specifically by inhibiting cytochrome P450 3A (CYP3A) enzymes. This inhibition reduces the metabolism of co-administered drugs, thereby increasing their plasma concentrations and therapeutic efficacy. It is primarily used to boost the potency of certain antiviral medications, such as those for HIV and Hepatitis C.

2. How long is the typical patent protection period for cobicistat and its related drug products? The patent protection period for cobicistat and its related drug products varies based on patent filings and jurisdiction. Generally, composition of matter patents for novel molecules like cobicistat have a lifespan of 20 years from the filing date, subject to potential extensions for regulatory review delays (e.g., in the US, via patent term extension). Process patents and formulation patents offer additional layers of protection with their own expiry dates.

3. What are the implications of cobicistat's patent expiry for API suppliers? Upon patent expiry of the innovator drugs that use cobicistat, the market opens to generic manufacturers. This typically leads to an increased demand for cobicistat API from multiple sources, driving down API prices due to heightened competition. Suppliers must then compete on cost-efficiency, quality, and regulatory standing to secure business from generic drug makers.

4. Can companies manufacture cobicistat API without a direct license from the innovator company, assuming relevant patents have expired? Yes, provided that all relevant patents covering the composition of matter, manufacturing processes, and specific polymorphic forms have expired or that the new manufacturer can develop a non-infringing process. A thorough Freedom to Operate (FTO) analysis is essential to ensure no active patents are being infringed. Regulatory approval of the manufacturing site and the API itself (via DMF filing) is also mandatory.

5. What are the most common impurity concerns in cobicistat manufacturing, and how are they managed? Common impurity concerns in cobicistat synthesis can arise from incomplete reactions, side reactions, residual starting materials or intermediates, degradation products, and residual solvents. Manufacturers manage these by implementing robust process controls, optimizing reaction conditions to minimize side product formation, employing effective purification techniques (e.g., crystallization, chromatography), and developing validated analytical methods to detect and quantify impurities according to stringent pharmacopeial and regulatory limits.

Citations

[1] United States Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [USPTO website]

[2] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from [EPO website]

[3] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice. Retrieved from [FDA website]

[4] European Medicines Agency. (n.d.). Manufacturing. Retrieved from [EMA website]

[5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website]